Diagnosis of the disease requires a combination of clinical performance, imaging, laboratory testing and pathological activation. The platform can assist in linking a team of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. Treatment and management of the treatment of the DNA of the metastatic myocardium require individualized development, typically including drug therapy, rehabilitation interventions, and regular follow-up management.
In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many previously difficult-to-treat genetic metabolic disorders have been significantly improved. Treatment needs to be closely monitored for efficacy and adverse reactions, adapted to timely scheduling according to disease changes. Multidisciplinary collaboration (MDT) is particularly important for the integrated management of mitochondrial DNA exhaustion syndrome and cardiomyopathy.
2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4.
Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.